TITLE

Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis

PUB. DATE
October 2004
SOURCE
CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p992
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
20558618

 

Related Articles

  • Infliximab and etanercept: serious infections and tuberculosis.  // WHO Drug Information;2004, Vol. 18 Issue 4, p275 

    Focuses on the effect of tumor necrosis factor-alpha (TNF-α) antagonist in the treatment of signs and symptoms of rheumatoid arthritis and other autoimmune diseases. Indication of Remicade and Etanercept in adults for rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis in...

  • NEW ANTI-INFLAMMATORY DRUGS INCREASE TB RISK. Kaye, Donald // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, Preceding p1 

    The article reports that the new anti-inflammatory drugs increase tuberculosis risk. Recently developed drugs called TNF-blockers have brought relief to many people with inflammatory conditions such as rheumatoid arthritis or Crohn's disease. However, the drugs do carry a risk. In a report,...

  • Anti-TNFα drugs linked to HBV reactivation.  // Reactions Weekly;1/28/2006, Issue 1086, p2 

    Focuses on the public health advisory letter issued by manufacturers of the anti-tumor necrosis factor products, Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab), concerning the possible association between use of the drugs and reactivation of hepatitis B virus (HBV) infection,...

  • Biologics Update. Hilton, Lisette // Dermatology Times;Nov2003, Vol. 24 Issue 11, p28 

    Describes four biologics that can treat psoriasis. Alefacept, an amevive from Biogen; Efalizumab, a raptiva from Genentech; Enbrel, an etanercept from Amgen Corp.; Infliximab, a remicade from Centocor; Usage procedure; Side effects; Level of effectiveness; Remissions; Clearance rate; Prospects...

  • Warning in NZ about TNF antagonist-related HBV reactivation.  // Reactions Weekly;11/18/2006, Issue 1128, p2 

    The article reports on the issuance of a Dear Healthcare Professional letter by New Zealand's Medsafe regarding hepatitis B virus reactivation. Such reactivation occurred in patients receiving tumor necrosis factor antagonists Enbrel or etanercept, Humira or adalimumab and Remicade of...

  • RA hope as NICE set to reconsider guidance.  // GP: General Practitioner;6/15/2007, p3 

    The article focuses on the National Institute of Clinical Exellence's (NICE) plan to reconsider its draft guidance on the use of a second anti-tumor-necrosis factor (TNF) drug for treating rheumatoid arthritis (RA) in Great Britain. The drugs referred in the NICE appeal are infliximab...

  • Immunosuppressive drugs may pose threat in transplant patients. Guttman, Cheryl // Dermatology Times;Apr2004, Vol. 25 Issue 4, p41 

    Reports that immunosuppressive drugs may pose threat in transplant patients. Overview of the risks associated with immunosuppressive drugs by Dr. Lebwohl, professor and chair, department of dermatology, Mount Sinai School of Medicine; Suppression of immune system by biologic agents infliximab...

  • Tuberculosis Cases Associated with Infliximab and Etanercept. Winthrop, Kevin L.; Siegel, Jeffrey N. // Clinical Infectious Diseases;10/15/2004, Vol. 39 Issue 8, p1256 

    Presents a letter to the editor focusing on tuberculosis cases associated with infliximab and etanercept.

  • TNF-blocker triple approval. Netterwald, James // Nature Biotechnology;Jun2009, Vol. 27 Issue 6, p495 

    The article reports on the approval of Simponi-branded golimumab by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Simponi, a tumor necrosis factor alpha (TNF-α) blocker manufactured by Johnson & Johnson's...

  • Infection rates differ with tumor necrosis factor inhibitors.  // Drug Topics;11/3/2003, Vol. 147 Issue 21, p9 

    Reports on variation of infection rates with administration of tumor necrosis factor inhibitors for treatment of rheumatoid arthritis in the U.S. Detection of increased risk of tuberculosis and pneumonia in patients treated with etanercept; Comparison with infliximab.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics